News Column

PeptiMed Signs Agreement with the National Cancer Institute to Assess Safety of HelpTM Drug Delivery Nanoparticle Formulations

June 25, 2014

The nanocomplex materials to be provided by PeptiMed will harbor motifs that bind to cell adhesion molecules on the surface of cancer cells and deliver an siRNA payload that silences the oncogene, EVI1. Initially, the NCL will assess the physical and chemical properties of the nanocomplexes followed by their purity and sterility in cell culture models. A second phase of testing for various modes of toxicity may be performed in animal models.

"We are profoundly pleased to work with the NCL to further our understanding of PeptiMed nanomaterials," stated Scott Schneider, CEO and co-founder of PeptiMed. "We are indeed fortunate to be able to rely on the expertise of the professionals at the NCL to get one step closer to the clinic."

PeptiMed co-founder Dr. Jeremy Heidel added, "The NCL has a strong track record in assisting biotech companies [as well as government and academic institutions] with evaluation and development of novel nanoparticle drug delivery systems. The comprehensive battery of measurements to be performed at the NCL will provide data and analytical methods that will help advance our nanoparticle technology toward the clinic."

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Global Data Point

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters